

**MINUTES OF THE MEETING OF THE CUMBRIA AREA PRESCRIBING COMMITTEE**  
**HELD ON THURSDAY 15<sup>th</sup> OCTOBER, 2015 AT 2.00PM**  
**PENRITH RUGBY CLUB**

<b>Present:</b> Bill Glendinning Lesley Angell Pauline Bourne Andrea Loudon Dr Andrea Mulgrew Dr Julia Smith Dr Nirmalan Arulanantham Ros Brown Phil Utting Helena Gregory Judi Matthews (in part)	Chief Pharmacist, NCUHT (Chair) Senior Medicines Optimisation Pharmacist, NECS Senior Pharmacist, UHMBT Clinical Pharmacy Lead, CCG GP Prescribing Lead, Allerdale Locality GP Prescribing Lead, South Lakes Locality Consultant Physician, NCUHT Pharmacist, NCUHT Senior Technician, Medicines Optimisation, NECS Medicines Optimisation Pharmacist North Lead Medicines Optimisation Pharmacist
<b>In Attendance:</b> Christine Nicholson	Admin Assistant, NECS

---

<b>25/15</b>	<b>APOLOGIES FOR ABSENCE</b>	<i>Action</i>
--------------	------------------------------	---------------

**Apologies for absence were received from:**  
 Helen Huck, Lead Pharmacist CPFT  
 Ben Merriman, LPC Representative  
 Dr Amanda Pugh, GP Prescribing Lead, Furness Locality  
 Sarah Roberts, Patient Voice representative

---

<b>26/15</b>	<b>DECLARATION OF INTERESTS</b>	
--------------	---------------------------------	--

NONE

Declaration of interests were discussed with reference to Lothian Formulary Declaration of Interests Policy Statement. **LA**  
 LA to develop Annual Declaration of Interest Form to be considered at next meeting.

---

<b>27/15</b>	<b>MINUTES OF THE PREVIOUS MEETING</b>	
--------------	--	--

The minutes of the previous meeting held on 13<sup>th</sup> August 2015 were agreed with one amendment that action point 69/14 was COMPLETED.

---

<b>28/15</b>	<b>ACTION LOG FROM PREVIOUS MEETING (30 April 2015)</b>	
--------------	---	--

Updates were given as follows:  
 70/14 – This action was completed  
 85/14 – This action was completed  
 15/15 – This action was completed  
 61/15 & 74/15 – This action was completed  
 66/15 – This action was completed  
 80/15 – This action was completed  
 81/15 – This action was completed

---

82/15 – This action was completed  
84/15 – This action was completed  
85/15 – This action was completed  
89/15 – This action was completed  
91/15 – This action was completed  
93/15 – This action was completed  
94/15 – This action was completed  
95/15 – This action was completed

**70/14 – Revised Dosing for Domperidone use in babies and children position statement**  
Maintain Domperidone as RED on RAG list, bring SCP to future meeting when available - COMPLETED

**85/14 – Primary Care Management of Cellulitis** – Acute and Community providers will work together to provide this service - COMPLETED

**114/14 - Bring proposal for dementia patients reviews as part of the SCG**  
Removed until further notice- CLOSED

**134/14 – Draft a statement about the second line use of anti-TNFs for psoriatic arthritis in line with the decision of the IFR panel.**  
Statement was approved in August meeting – to be added to Blueteq.

**15/15- Nabilone**  
NCUHT – ongoing discussions with current patients; no new patients being prescribed Nabilone - COMPLETED

**33/15 - NICE CG Medicines Optimisation** – The CCG part completed Baseline Assessment was discussed. This is to become a standing agenda item with discussion focusing on:

- Medicines and patient safety
- Patient decision aids

Provider Trusts to bring completed Baseline Assessments to the next meeting.

**54/15 – Rituximab** – LA to seek information on position in other NE CCGs - ONGOING

**61/15 & 74/15 - Infliximab Biosimilars** – In contract review process – COMPLETED

**66/15 – Insulin Degludec** – BG shared Sunderland guidelines, currently BLACK – re-categorise as RED on RAG list (only in line with NICE NG17)– COMPLETED

**72/15 - NG 14-Melanoma – assessment & management** – Review current Vitamin D guidelines to ensure NG14 is followed - ONGOING

**80/15 - Denosumab 120mg – SCG proposal** – Trusts to progress financial discussions in house, unable to progress via Medicines Management – COMPLETED

**81/15 Midrodrene – Review of RAG rating** – Now licensed for the treatment of Orthostatic hypotension due to autonomic dysfunction. Status now AMBER for the treatment of Orthostatic hypotension due to autonomic dysfunction. - COMPLETED

**82/15 Fludrocortisone review** – Current RAG status GREEN, remains 1<sup>st</sup> line for the treatment of Orthostatic hypotension due to autonomic dysfunction in line with the European Neurology Society guidelines - COMPLETED

---

LA

PU

BG  
PB

LA

LA

LA

---

**84/15 Ciclosporin SCG** – Changes made at August meeting have been included with the exception of

- Platelets < 150 x 10<sup>9</sup>/L or less than the lower limit of reference range as per lab

Which remains because of national guidance and is in line with all other SCP- APPROVED

**85/15 Liothyronine evidence review** – Consultant comments on place in therapy noted. Approved RED on RAG list for cancer patients; BLACK on RAG list for all other indications - COMPLETED

**89/15 Commissioned Service for adult ADHD** – service in process of being commissioned in Cumbria - COMPLETED

**91/15 Drug Safety Update**

June 2015 – Add to Prescription Pad - COMPLETED

July 2015 – Add to Prescription Pad - COMPLETED

**93/15 Just in Case Medication sheet** – Sept 15 form brought back with changes for formal approval – APPROVED - COMPLETED

**94/15 Proposal for branded Oxycodone Prescribing** – Discussed, APC has previously agreed to support branded prescribing of opioids following the MHRA safety alert. Choice of product for oxycodone discussed, agreed LONGTEC MR tablets and SHORTEC liquid for breakthrough pain. - COMPLETED

**95/15 Naloxegol NICE TA345 (from Aug15)** – Impact assessment noted, RAG rating GREEN - COMPLETED

---

96/15 **RECENT LJF NEW DRUG RECOMMENDATIONS**

No new drug recommendations

**LJF AMENDMENTS** – noted

---

97/15 **NICE TECHNOLOGY APPRAISALS**

**TA351 Cangrelor** – For reducing atherothrombotic events in people undergoing percutaneous coronary intervention - BLACK

**TA352 Vedolizumab** – For treating moderately to severe active Crohn's disease after prior therapy – RED

**TA353 Bevacizumab** – For treating relapsed, platinum resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer - BLACK

**TA354 Edoxaban** – For treating and preventing recurrent deep vein thrombosis or pulmonary embolism - GREEN

**TA355 Edoxaban (Lixiana)** – Recommended as an option for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation who have one or more risk factors - GREEN

**TA356 Ruxolitinib** – For treating polycythaemia vera resistant to hydroxycarbamide or for

---

---

people who cannot tolerate hydroxycarbamide - BLACK

**TA357 Pembrolizumab** – Possible treatment for adults with melanoma - RED

---

98/15 **NICE CLINICAL GUIDELINES**

**NG15 Antimicrobial Stewardship** - Noted

**NG17 Type 1 Diabetes in adults, diagnosis and treatment** - Noted reduced HbA1C target produces better outcomes. Increased focus on patient education. Noted changes to first and second line Insulin regimes. AL to share Nice Associate information.

AL

**NG18 Diabetes (type 1 and type 2) in children and young people: diagnosis and management** – Noted

**NG19 Diabetic foot problems: prevention and management** – No medicine implications- Noted

**NG20 Coeliac disease: recognition, assessment and management** – Deferred to next meeting

**NG21 Homecare: delivering personal care and practice support to older people living in their homes** – Implications for providers noted.

---

99/15 **NICE Quality Standard (Draft)**

Draft document discussed, organisations encouraged to register as stakeholders and use this opportunity to be involved by commenting on the draft.

---

100/15 **CONTRACT MONITORING**

Blueteq patient numbers will be shared with contracting department, progress with getting patients on to the system will be monitored.

---

101/15 **MEDICINES SAFETY**

First meeting of MSO's took place in September, all Trusts were represented, issues shared, next meeting arranged early December to share learning.

---

**CLINICAL MATTERS**

102/15 **NTAG – Infliximab Biosimilars – Infectra and Remsima (updated 8<sup>th</sup> Sept)** – Clarification of previous recommendation - APPROVED

103/15 **NTAG – Certolizumab pegol for the treatment of Psoriatic Arthritis** – Reviewed and approved previously as a flex- APPROVED

104/15 **NTAG – The use of sequential TNF Inhibitors in the management of Psoriatic Arthritis** – Reviewed and approved for use previously - APPROVED

105/15 **NTAG – Orthotic functional electrical stimulation (FES) for foot drop of neurological origin** – Noted – no medicines implications.

---

106/15	<b>Green Bag Scheme</b> – BG to check with NWAS if there are any schemes running currently in the North West. Possible future topic for the North West Clinical Pharmacy Forum - ONGOING	<b>BG</b>
107/15	<b>NECS Antimicrobial quality premium 2015/16 briefing paper</b> – LA to bring quarterly data to APC meetings for discussion; guidelines currently being updated. NECS are holding an antimicrobial prescribing conference on November 19 <sup>th</sup> in Newcastle.	
108/15	<b>Guidelines for the use of Feminising Hormone therapy in gender dysphoria</b> - Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval - ONGOING	<b>LA</b>
109/15	<b>Guidelines for the use of Masculinising Hormone therapy in gender dysphoria</b> – Suggested changes to include local details to be incorporated into document and brought back to next meeting for approval - ONGOING	<b>LA</b>
110/15	<b>NOAC Counselling Checklist</b> - Updated version discussed. Committee requested the addition of an additional box for the use of a patient decision aid in line with NICE guidance. COMPLETED	
111/15	<b>Sulfasalazine SCG</b> – PB to check with gastroenterologists whether gastro indications should be included; query re requirements for patient monitoring – ONGOING to be brought back to the next meeting	<b>PB</b>
112/15	<b>Tocilizumab – New Medicine Review</b> – pathway APPROVED	
113/15	<b>RAG rating review: Co-Enzyme Q10</b> – RAG rating BLACK - COMPLETED	
114/15	<b>Prescribing review: Pregabalin &amp; Gabapentin</b> – Deferred to next meeting	
115/15	<b>Prescribing review: Strong Opioids</b> – Deferred to next meeting	
116/15	<b>Prescribing review: Antidepressants</b> – Deferred to next meeting	
117/15	<b>Prescribing review: Antipsychotics</b> – Deferred to next meeting	
118/15	<b>Prescribing review: LHRH agonists</b> – Deferred to next meeting	
119/15	<b>Prescribing review: Anticholinergic drugs for urinary incontinence :</b> Recommendation 1 – ENDORSED – Mirabegron - RED in combination with other anticholinergics. Recommendation 2 – ENDORSED – use of immediate release Tolteridone	
120/15	<b>Leflunomide SCG</b> – Amendments agreed. Alcohol use in line with British Rheumatology Society suggested levels. UKMI guidance on lactose content of medicines followed. Monitoring in line with British Rheumatology Society recommendations. Final version to be brought to the next meeting for final approval	<b>PB</b>
121/15	<b>Insulin Glargine Biosimilar – Abasagler</b> – to be brought to next meeting; LA to circulate NECS briefing paper.	<b>LA</b>

---

122/15 **OPERATIONAL**

---

123/15 **DRUG SAFETY UPDATE**

Drug Safety Update (August 2015) – Noted, specialist use only

Drug Safety Update (September 2015) – Risk of Subcutaneous Lupus Erythematosus with PPI's – add to Prescription Pad **LA**

The Cumbria yellow card report to be brought to next meeting **AL**

---

124/15 **FOR INFORMATION**

**Minutes received:**

NTAG (8<sup>th</sup> September, 2015)

Lothian Formulary Committee (8<sup>th</sup> July, 2015)

Lothian Formulary Committee (2<sup>nd</sup> September, 2015)

---

125/15 **ANY OTHER BUSINESS**

In future all APC papers will be hosted on the NECS Medicines Optimisation Website **PU**

---

**DATE and TIME of next meeting**

**Thursday, 17<sup>th</sup> December 2015, 2pm at Enterprise House, Kendal**

---